Prevalence and prognosis of patients with breast cancer eligible for adjuvant abemaciclib or ribociclib: a nationwide population-based studyResearch in context

Summary: Background: Nationwide studies on the prevalence, characteristics and long-term prognosis of patients with early breast cancer and a potential indication for adjuvant CDK4/6 inhibitors are lacking. Methods: We leveraged a prospectively collected nationwide cohort of all patients treated fo...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Xingrong Liu, Behnaz Binicy, Balazs Acs, Louise Eriksson Bergman, Sibylle Loibl, Michael Gnant, Michael Untch, Antonios Valachis, Jonas Bergh, Johan Hartman, Theodoros Foukakis, Alexios Matikas
Format:	Artigo
Jezik:	Inglês
Izdano:	Elsevier 2025-12-01
Serija:	The Lancet Regional Health. Europe
Teme:	Abemaciclib Adjuvant Breast cancer CDK4/6 inhibitors monarchE NATALEE
Online dostop:	http://www.sciencedirect.com/science/article/pii/S2666776225002637
Oznake:	Označite Brez oznak, prvi označite!